Sanofi to provide discounts for Zaltrap
Sanofi (Euronext:SAN; NYSE:SNY) said it is working on agreements with the "U.S. oncology community" to provide discounts of about 50% for metastatic colorectal cancer (mCRC) drug Zaltrap ziv-aflibercept. Sanofi, which launched the drug in late August, said Zaltrap is "priced competitively" but added there has been "market resistance to the perceived relative price of Zaltrap." Last month, doctors from Memorial Sloan-Kettering Cancer Center published an Op-Ed in The New York Times stating that the hospital will no longer prescribe Zaltrap, citing the drug's cost vs. Avastin.
Zaltrap is approved in combination with FOLFIRI chemotherapy to treat mCRC that is resistant to or has progressed following an oxaliplatin-containing regimen. In 3Q12, Sanofi recorded EUR 7 million ($9 million) in U.S. sales of Zaltrap. ...